September 30, 2023

December 31, 2022

Assets

Current assets:

Cash and cash equivalents

$

10,611

$

20,644

Short-term investments

5,089

—

Accounts receivable and other receivables, net of allowance for doubtful accounts of
   $0 and $3 as of September 30, 2023 and December 31, 2022, respectively

304

1,221

Inventories, net — current

2,657

2,321

Assets held for sale

87

87

Prepaid expenses and other current assets

1,093

795

Current assets of discontinued operations

165

330

Total current assets

20,006

25,398

Property and equipment, net

468

680

Right of use asset

1,147

1,848

Inventories, net — noncurrent

1,624

767

Intangible assets, net

40

40

Other noncurrent assets

181

165

Noncurrent assets of discontinued operations

—

24

Total assets

$

23,466

$

28,922

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable and accrued expenses

$

2,602

$

2,855

Amounts due to related parties

46

48

Operating lease liability — current

924

1,010

Other current liabilities

282

270

Current liabilities of discontinued operations

31

26

Total current liabilities

3,885

4,209

Operating lease liability — noncurrent

347

1,007

Common stock warrant and option liabilities

1,836

806

Other noncurrent liabilities

2,000

2,000

Total liabilities

8,068

8,022

Commitments and contingencies (Note 13)

Stockholders’ equity:

Common stock, $0.001 par value—150,000,000 shares authorized as
   of September 30, 2023 and December 31, 2022; 1,110,337 and 616,079 shares issued
   and outstanding as of September 30, 2023 and December 31, 2022, respectively

65

65

Additional paid-in capital

284,371

278,827

Accumulated other comprehensive income

87

—

Accumulated deficit

(268,987

)

(257,859

)

Total stockholders’ equity

15,536

21,033

Non-controlling interest

(138

)

(133

)

Total stockholders' equity

15,398

20,900

Total liabilities and stockholders’ equity

$

23,466

$

28,922

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Revenues:

Product

$

1,597

$

1,543

$

4,150

$

5,685

Royalty

—

17

—

117

License

—

10

10

872

Total revenues

1,597

1,570

4,160

6,674

Operating expenses (income):

Cost of revenues

1,102

1,128

2,630

5,201

Research and development

305

255

1,055

1,009

Gain on sale of Verdeca

—

—

—

(1,138

)

Change in fair value of contingent consideration

—

—

—

(70

)

Gain on sale of property and equipment

(11

)

—

(36

)

(386

)

Selling, general and administrative

3,443

4,178

11,085

11,407

Total operating expenses

4,839

5,561

14,734

16,023

Loss from continuing operations

(3,242

)

(3,991

)

(10,574

)

(9,349

)

Interest income

133

95

538

123

Other income, net

17

43

36

13

Valuation loss on March 2023 PIPE

—

—

(6,076

)

—

Change in fair value of common stock warrant and option liabilities

608

1,880

5,965

1,880

Issuance and offering costs allocated to liability classified options

—

(314

)

(430

)

(314

)

Net loss from continuing operations before income taxes

(2,484

)

(2,287

)

(10,541

)

(7,647

)

Income tax provision

—

(1

)

(1

)

(1

)

Net loss from continuing operations

(2,484

)

(2,288

)

(10,542

)

(7,648

)

Net loss from discontinued operations

(83

)

(589

)

(591

)

(3,636

)

Net loss

(2,567

)

(2,877

)

(11,133

)

(11,284

)

Net loss attributable to non-controlling interest

—

(10

)

(5

)

(152

)

Net loss attributable to common stockholders

$

(2,567

)

$

(2,867

)

$

(11,128

)

$

(11,132

)

Net loss per share attributable to common stockholders:

Basic and diluted from continuing operations

$

(1.83

)

$

(3.71

)

$

(8.81

)

$

(13.05

)

Basic and diluted from discontinued operations

$

(0.06

)

$

(0.96

)

$

(0.49

)

$

(6.33

)

Net loss per basic and diluted share attributable to common stockholders

$

(1.89

)

$

(4.67

)

$

(9.31

)

$

(19.37

)

Weighted-average number of shares used in per share
   calculations:

Basic and diluted

1,359,511

613,814

1,195,354

574,621

Other comprehensive income, net of tax

Unrealized gains on available-for-sale securities

$

66

$

—

$

87

$

—

Other comprehensive income

$

66

$

—

$

87

$

—

Nine Months Ended September 30,

2023

2022

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss

$

(11,133

)

$

(11,284

)

Adjustments to reconcile net loss to cash used in operating activities:

Change in fair value of common stock warrant and option liabilities

(5,965

)

(1,880

)

Change in fair value of contingent consideration

—

(70

)

Issuance and offering costs allocated to liability classified options

430

314

Valuation loss on March 2023 PIPE

6,076

—

Depreciation

227

354

Amortization of intangible assets

—

39

Lease amortization

535

686

Impairment of intangible assets

—

72

Gain on disposal of property and equipment

(36

)

(386

)

Stock-based compensation

573

897

Bad debt expense

—

32

Gain on sale of Verdeca

—

(1,138

)

Write-down of inventories

444

1,530

Impairment of property and equipment

—

370

Changes in operating assets and liabilities:

Accounts receivable and other receivables

249

(534

)

Inventories

(1,388

)

1,071

Prepaid expenses and other current assets

(284

)

(90

)

Other noncurrent assets

(13

)

15

Accounts payable and accrued expenses

(300

)

(890

)

Amounts due to related parties

(2

)

(17

)

Other current liabilities

11

6

Operating lease liabilities

(573

)

(718

)

Net cash used in operating activities

(11,149

)

(11,621

)

CASH FLOWS FROM INVESTING ACTIVITIES:

Proceeds from sale of property and equipment

42

897

Proceeds from sale of Verdeca — earn-out received

569

285

Purchases of property and equipment

(5

)

(46

)

Purchases of investments

(5,002

)

—

Net cash (used in) provided by investing activities

(4,396

)

1,136

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock, pre-funded warrants and
   preferred investment options from March 2023 PIPE

5,997

—

Payments of offering costs relating to March 2023 PIPE

(497

)

—

Proceeds from issuance of common stock, pre-funded warrants and
   preferred investment options from August 2022 Offering

—

5,000

Payments of offering costs relating to August 2022 Offering

—

(488

)

Proceeds from ESPP purchases

12

7

Net cash provided by financing activities

5,512

4,519

Net decrease in cash and cash equivalents

(10,033

)

(5,966

)

Cash and cash equivalents — beginning of period

20,644

28,685

Cash and cash equivalents — end of period

$

10,611

$

22,719

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest

$

—

$

1

NONCASH INVESTING AND FINANCING ACTIVITIES:

Common stock warrant liabilities reclassified to equity upon adoption of ASU 2020-06

$

—

$

3,392

Common stock options issued to placement agent and included in offering costs related to August 2022 RDO securities purchase agreement

$

—

$

191

Common stock options issued to placement agent and included in offering costs related to March 2023 PIPE

$

212

$

—

Right of use assets obtained in exchange for new operating lease liabilities

$

—

$

114

Proceeds from sale of Verdeca in accounts receivable and other receivables

$

—

$

854

Warrant and option modifications included in Valuation loss on March 2023 PIPE

$

404

$

—